Quality-adjusted cost of care: A meaningful way to measure growth in innovation cost versus the value of health gains

Health Affairs

Volumn 34, Issue 4, 2015, Pages 555-561

  Lakdawalla, Darius ^a   Shafrin, Jason ^b   Lucarelli, Claudio ^c   Nicholson, Sean ^d   Khan, Zeba M ^e   Philipson, Tomas J ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PRECISION HEALTH ECONOMICS   (United States)

^c UNIVERSIDAD DE LOS ANDES   (Chile)

^d Department of Obstetrics Gynecology   (United States)

^e CELGENE CORPORATION   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; LENALIDOMIDE; MELPHALAN; OXALIPLATIN; PREDNISONE; THALIDOMIDE;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG COST; HEALTH CARE COST; HUMAN; MULTIPLE MYELOMA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; EXPERIMENTAL THERAPY; TRENDS;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; MULTIPLE MYELOMA; QUALITY-ADJUSTED LIFE YEARS; THERAPIES, INVESTIGATIONAL;

EID: 84929622991     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0639     Document Type: Article

References (27)

1. Congressional Budget Office. The 2013 long-term budget outlook [Internet]. Washington (DC): CBO; 2013 Sep [cited 2014 Dec 23]. Available from: https://www.cbo .gov/sites/default/files/44521-LTBO2013_0.pdf
2. Medicare Payment Advisory Commission. Report to the Congress:Medicare payment policy [Internet]. Washington (DC): MedPAC; 2014 Mar [cited 2014 Dec 23]. Available from: http://www.medpac.gov/ documents/reports/mar14_entire report.pdf?sfvrsn=0
3. Chernew M, Newhouse JP. Health care spending growth. In: Pauly MV, McGuire TG, Barros PP, editors. Handbook of health economics. Vol.2. Amsterdam: North Holland; 2012.
4. Philipson TJ, Jena AB.Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum Health Econ Policy. 2006;9(2):article 3.
5. Lucarelli C, Nicholson S. A qualityadjusted price index for colorectal cancer drugs [Internet]. Cambridge (MA): National Bureau of Economic Research; 2009 Jul [cited 2014 Dec 23]. (NBER Working Paper No. 15174). Available from: http:// www.nber.org/papers/w15174.pdf
6. Cutler DM, McClellan M, Newhouse JP, Remler D. Are medical prices declining? Evidence from heart attack treatments. Q J Econ. 1998; 113(4):991-1024.
7. Dunn A. Drug innovations and welfare measures computed from market demand: the case of anti-cholesterol drugs. Am Econ J Appl Econ. 2012;4(3):167-89.
8. National Cancer Institute. Colon and rectal cancer [Internet]. Bethesda (MD): NCI; [cited 2014 Dec 23]. Available from: http://www.cancer .gov/cancertopics/types/colon-andrectal
9. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract. 2011;7(3S):e30s-e37s.
10. Food and Drug Administration. FDA background for Colon Cancer Endpoints Workshop [Internet]. Silver Spring (MD): FDA; 2003 [cited 2014 Dec 30]. Available from: http:// www.fda.gov/downloads/About FDA/CentersOffices/CDER/ ucm120847.pdf
11. Bir A, Tan W,Wilding GE, Lombardo J, Fakih MG. 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. Oncology. 2007;72(1-2):4-9.
12. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertain. 2003; 27(1):5-76.
13. Cutler DM. Your money or your life:strong medicine for America's health care system. Oxford: Oxford University Press; 2004.
14. Ryen L, Svensson M. The willingness to pay for a quality adjusted life year:a review of the empirical literature. Health Econ. 2014 Jul 28. [Epub ahead of print].
15. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009; 374(9686):324-39.
16. American Cancer Society. Multiple myeloma [Internet]. Atlanta (GA):The Society; [last revised 201 2014 Jun 16; cited 2014 Dec 23]. Available from: http://www.cancer.org/ cancer/multiplemyeloma/ detailedguide/multiple-myelomakey- statistics
17. Food and Drug Administration. US package insert: FDA/MPI finalized:Celgene Corp.: RevlimidTM (lenalidomide) [Internet]. Silver Spring (MD): FDA; 2006 [cited 2014 Dec 30]. Available from: http:// www.accessdata.fda.gov/ drugsatfda_docs/label/2006/021880s001.pdf
18. Food and Drug Administration. US package insert: FDA/MPI finalized:Millennium Pharmaceuticals, Inc.:VelcadeTM (bortezomib) for injection [Internet]. Silver Spring (MD): FDA; 2003 May 13 [cited 2014 Dec 23]. Available from: http://www.access data.fda.gov/drugsatfda_docs/ label/2003/021602lbl.pdf
19. Brown RE, Stern S, Dhanasiri S, Schey S. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ. 2013;14(3):507-14.
20. Bureau of Labor Statistics. Consumer Price Index [Internet]. Washington (DC): BLS; [cited 2014 Dec 23]. Available for download from: http:// www.bls.gov/cpi/
21. Newhouse JP, Garber A. Geographic variation in health care spending and promotion of high-value care. Washington (DC): National Academies Press; 2010.
22. RTI International, Telligen. Accountable care organization 2013 program analysis: quality performance standards narrative measure specifications. Baltimore (MD):Centers for Medicare and Medicaid Services; 2012.
23. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2006;67(8):1194-203.
24. Hoyle M, Rogers G, Garside R, Moxham T, Ken Stein (Peninsula Technology Assessment Group, Exeter, England). The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene [Internet]. London: National Institute for Health and Care Excellence; 2008 Sep 1 [cited 2014 Dec 23]. Available from: http://www.nice.org.uk/ guidance/ta171/resources/multiplemyeloma- lenalidomide-evidencereview- group-report2
25. Durie B, Binder G, Pashos C, Khan Z, Hussein M, Borrello I. Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ. 2013;16(5):614-22.
26. Bentley TS, Hanson SG. 2011 U.S. organ and tissue transplant cost estimates and discussion [Internet]. Seattle (WA): Milliman; 2011 Apr [cited 2014 Dec 23]. (Milliman Research Report). Available from:http://publications.milliman.com/ research/health-rr/pdfs/2011-usorgan- tissue.pdf
27. Dunavin NC,Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, et al. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma. 2013;54(8):1658-64.